Breaking News

Over a quarter ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Oncopeptides to host business news update conference call » 14:55
01/24/22
01/24
14:55
01/24/22
14:55
ONPPF

Oncopeptides

/

+

CEO Lindberg and CMO…

CEO Lindberg and CMO Bakker hold a business news update conference call on January 24 at 3 pm. Webcast Link

ShowHide Related Items >><<
ONPPF Oncopeptides
/

+

ONPPF Oncopeptides
/

+

10/25/21 DNB Markets
Oncopeptides downgraded to Sell from Buy at DNB Markets
10/22/21 H.C. Wainwright
H.C. Wainwright sees bankruptcy risk for Oncopeptides after withdrawal
07/29/21 H.C. Wainwright
Oncopeptides price target lowered to SEK 12 from SEK 48 at H.C. Wainwright
07/13/21 H.C. Wainwright
Oncopeptides downgraded to Sell from Buy at H.C. Wainwright
Conference/Events
Oncopeptides to host business news update conference call » 11:17
01/24/22
01/24
11:17
01/24/22
11:17
ONPPF

Oncopeptides

/

+

CEO Lindberg and CMO…

CEO Lindberg and CMO Bakker hold a business news update conference call on January 24 at 3 pm. Webcast Link

ShowHide Related Items >><<
ONPPF Oncopeptides
/

+

ONPPF Oncopeptides
/

+

10/25/21 DNB Markets
Oncopeptides downgraded to Sell from Buy at DNB Markets
10/22/21 H.C. Wainwright
H.C. Wainwright sees bankruptcy risk for Oncopeptides after withdrawal
07/29/21 H.C. Wainwright
Oncopeptides price target lowered to SEK 12 from SEK 48 at H.C. Wainwright
07/13/21 H.C. Wainwright
Oncopeptides downgraded to Sell from Buy at H.C. Wainwright
Downgrade
Oncopeptides downgraded to Sell from Buy at DNB Markets » 05:12
10/25/21
10/25
05:12
10/25/21
05:12
ONPPF

Oncopeptides

$3.59 /

+ (+0.00%)

DNB Markets analyst…

DNB Markets analyst Patrik Ling double downgraded Oncopeptides to Sell from Buy with a SEK 5 price target.

ShowHide Related Items >><<
ONPPF Oncopeptides
$3.59 /

+ (+0.00%)

ONPPF Oncopeptides
$3.59 /

+ (+0.00%)

10/22/21 H.C. Wainwright
H.C. Wainwright sees bankruptcy risk for Oncopeptides after withdrawal
07/29/21 H.C. Wainwright
Oncopeptides price target lowered to SEK 12 from SEK 48 at H.C. Wainwright
07/13/21 H.C. Wainwright
Oncopeptides downgraded to Sell from Buy at H.C. Wainwright
Recommendations
H.C. Wainwright sees bankruptcy risk for Oncopeptides after withdrawal » 11:14
10/22/21
10/22
11:14
10/22/21
11:14
ONPPF

Oncopeptides

$3.59 /

+ (+0.00%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns keeps a Sell rating on Oncopeptides and removed the firm's price target after the company decided to withdraw Pepaxto from the U.S. market following interactions with the FDA around the OCEAN trial results. The analyst sees risk of a potential bankruptcy in the wake of the market withdrawal "due to the limited pipeline and lack of other value drivers."

ShowHide Related Items >><<
ONPPF Oncopeptides
$3.59 /

+ (+0.00%)

ONPPF Oncopeptides
$3.59 /

+ (+0.00%)

07/29/21 H.C. Wainwright
Oncopeptides price target lowered to SEK 12 from SEK 48 at H.C. Wainwright
07/13/21 H.C. Wainwright
Oncopeptides downgraded to Sell from Buy at H.C. Wainwright
Hot Stocks
Oncopeptides withdraws Pepaxto from U.S. market after Phase 3 study » 10:58
10/22/21
10/22
10:58
10/22/21
10:58
ONPPF

Oncopeptides

$3.59 /

+ (+0.00%)

Oncopeptides announced…

Oncopeptides announced that the company has decided to withdraw Pepaxto from the market in the U.S., following the Phase 3 OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the Food and Drug Administration. Pepaxto was granted accelerated approval on February 26, 2021. "During our dialogue with FDA it has become evident that the FDA does not consider that the phase 3 OCEAN study meets the criteria of a confirmatory study. Oncopeptides believes that the OCEAN data are scientifically meaningful and that the findings warrant further evaluation," the company said in a statement. Oncopeptides said it "will immediately refocus the company and return to being a Sweden based R&D company, dedicated to further develop our proprietary Peptide Drug Conjugate (PDC) platform including the next generation of drug candidates including OPD5 and OPDC3. The organization will be scaled down to increase our cash runway and focus on building a platform for longer term development and growth. The commercial business units in the US and Europe will be closed down and the Stockholm based organization will be significantly reduced."

ShowHide Related Items >><<
ONPPF Oncopeptides
$3.59 /

+ (+0.00%)

ONPPF Oncopeptides
$3.59 /

+ (+0.00%)

07/29/21 H.C. Wainwright
Oncopeptides price target lowered to SEK 12 from SEK 48 at H.C. Wainwright
07/13/21 H.C. Wainwright
Oncopeptides downgraded to Sell from Buy at H.C. Wainwright
Hot Stocks
Oncopeptides' CFO Anders Martin-Lof to leave company » 12:00
10/15/21
10/15
12:00
10/15/21
12:00
ONPPF

Oncopeptides

$3.59 /

+ (+0.00%)

Oncopeptides announced…

Oncopeptides announced that CFO Anders Martin-Lof has informed Oncopeptides that he will leave the company for personal reasons. Anders was appointed CFO in 2018 and has a six-month notice period. He will continue in his current role until a new temporary or permanent CFO takes office. A recruitment process will be initiated immediately. "Anders has been instrumental in the development of Oncopeptides from a R&D company to a fully integrated biotech company, and I am really grateful for his extraordinary commitment and contribution", says Marty J Duvall, CEO at Oncopeptides.

ShowHide Related Items >><<
ONPPF Oncopeptides
$3.59 /

+ (+0.00%)

07/29/21 H.C. Wainwright
Oncopeptides price target lowered to SEK 12 from SEK 48 at H.C. Wainwright
07/13/21 H.C. Wainwright
Oncopeptides downgraded to Sell from Buy at H.C. Wainwright
Recommendations
Oncopeptides price target lowered to SEK 12 from SEK 48 at H.C. Wainwright » 06:10
07/29/21
07/29
06:10
07/29/21
06:10
ONPPF

Oncopeptides

$11.14 /

+ (+0.00%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns lowered the firm's price target on Oncopeptides to SEK 12 from SEK 48 and keeps a Sell rating on the shares. The analyst says the incremental OCEAN trial survival data "paints a damning picture." He believes Pepaxto's accelerated approval is at risk of revocation.

ShowHide Related Items >><<
ONPPF Oncopeptides
$11.14 /

+ (+0.00%)

07/13/21 H.C. Wainwright
Oncopeptides downgraded to Sell from Buy at H.C. Wainwright
Downgrade
Oncopeptides downgraded to Sell from Buy at H.C. Wainwright » 06:11
07/13/21
07/13
06:11
07/13/21
06:11
ONPPF

Oncopeptides

$11.14 /

+ (+0.00%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns double downgraded Oncopeptides to Sell from Buy with a price target of SEK 48, down from SEK 155, following the company's OCEAN trial update and partial clinical hold announcement on July 8. The analyst sees an "inevitable near-term financing overhang." He anticipates Oncopeptides will have to raise at least an additional SEK1B by Q1 of 2022 to remain solvent and fund operations for another year. As such, the recent share price decline "would likely require more shares to be issued than previously estimated, increasing dilution," says Burns.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.